Covaxin neutralises double mutant strain, effective against multiple variants of SARS-CoV-2: ICMR
Bharat Biotech's Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the globe.
Share
Updated: Apr 21, 2021, 04:01 PM IST
Indigenously-developed Covid-19 vaccine Covaxin, made by Bharat Biotech, neutralises multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well, the Indian Council of Medical Research (ICMR) said on Wednesday.
"ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well," the ICMR tweeted.
This development comes amid the second wave of the COVID-19 pandemic being witnessed across the country.